Pfizer 2009 Annual Report Download - page 102

Download and view the complete annual report

Please find page 102 of the 2009 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 110

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Segment Assets, Property, Plant and Equipment Additions, and Depreciation and Amortization(a)
Additional details follow:
YEAR ENDED/AS OF DECEMBER 31,
(MILLIONS OF DOLLARS) 2009 2008 2007
Identifiable assets
Biopharmaceutical $120,789 $ 60,591 $ 67,431
Diversified 16,684 2,808 2,738
Discontinued operations/Held for sale 496 148 114
Corporate/Other(b), (c) 74,980 47,601 44,985
Total identifiable assets $212,949 $111,148 $115,268
Property, plant and equipment additions(d)
Biopharmaceutical $ 985 $ 1,351 $ 1,608
Diversified 147 265 146
Corporate/Other(b) 73 85 126
Total property, plant and equipment additions $ 1,205 $ 1,701 $ 1,880
Depreciation and amortization(d)
Biopharmaceutical $ 1,672 $ 2,223 $ 1,886
Diversified 113 108 94
Corporate/Other(b), (e) 2,972 2,759 3,220
Total depreciation and amortization $ 4,757 $ 5,090 $ 5,200
(a) Reflects legacy Wyeth amounts in 2009 commencing on the Wyeth acquisition date, October 15, 2009. Prior-period amounts for Capsugel, which
were previously classified in Corporate/Other, are now classified in Diversified.
(b) Corporate/Other includes Pfizer Centersource, which includes contract manufacturing and bulk pharmaceutical chemical sales and transition activity
associated with our former consumer healthcare business (sold in December 2006).
(c) Assets included within Corporate/Other are primarily cash and cash equivalents, short-term investments, and long-term investments and loans. In
2009, also includes $20.0 billion of goodwill resulting from our acquisition of Wyeth (see Note 2. Acquisition of Wyeth for additional information). The
allocation of goodwill among segments has not yet been completed but will be completed within one year from the acquisition date, October 15,
2009. Upon completion of the goodwill allocation, this goodwill will be reclassified to the appropriate segments.
(d) Certain production facilities are shared. Property, plant and equipment, as well as capital additions and depreciation, are allocated based on
estimates of physical production.
(e) Corporate/Other includes non-cash charges associated with purchase accounting related to intangible asset amortization of $2.7 billion in 2009,
$2.5 billion in 2008 and $3.1 billion in 2007.
Geographic(a)
Revenues and long-lived assets by geographic region are as follows:
(MILLIONS OF DOLLARS) YEAR ENDED/AS OF DECEMBER 31,
2009 2008 2007
Revenues
United States(b) $21,749 $ 20,401 $ 23,153
Europe 14,561 14,980 13,647
Japan/Other Asia 7,988 7,166 6,511
Canada/Latin America/AFME(c) 5,711 5,749 5,107
Consolidated $50,009 $48,296 $48,418
Long-lived assets(d)
United States(b) $50,901 $ 17,296 $ 19,145
Europe 32,015 12,220 15,416
Japan/Other Asia 4,966 1,080 1,177
Canada/Latin America/AFME(c) 2,913 412 494
Consolidated $90,795 $ 31,008 $ 36,232
(a) Reflects legacy Wyeth amounts in 2009 commencing on the Wyeth acquisition date, October 15, 2009.
(b) Includes operations in Puerto Rico.
(c) Includes Africa and the Middle East.
(d) Long-lived assets include identifiable intangible assets (excluding goodwill) and property, plant and equipment.
100 2009 Financial Report